We also provided the first experimental evidence that the GREM1-neutralizing antibody promoted differentiation of Lgr5+ intestinal stem cells and retarded CRC tumoroid growth only in a Smad4–wild-type setting, but not in Smad4-mutant tumoroids. Here, LGR5 is linked to colorectal carcinoma.